Abeclib 150 mg (Abemaciclib) Targeted Treatment for Advanced Breast Cancer
Abeclib 150 mg (Abemaciclib) is an oral chemotherapy medication used in the targeted treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This potent kinase inhibitor plays a crucial role in managing breast cancer that has progressed despite earlier endocrine therapy. It is manufactured by Eskayef Pharmaceuticals Ltd., a renowned pharmaceutical leader in Bangladesh, and globally supplied by Saif Pharma, a reliable oncology medicine distributor serving over 60 countries.
What is Abeclib 150 mg (Abemaciclib)?
Abeclib contains Abemaciclib, a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor. These kinases are responsible for promoting cell cycle progression from the G1 phase to the S phase. In hormone-positive breast cancers, these pathways are often overactive, causing uncontrolled cell division. Abeclib blocks this process, effectively slowing the growth and spread of cancer cells.
Indications for Use
Abeclib 150 mg is FDA-approved and used in the following clinical settings:
As monotherapy: For adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer who have experienced disease progression after endocrine therapy and chemotherapy in the metastatic setting.
In combination with an aromatase inhibitor: As initial endocrine-based therapy for postmenopausal women and men with HR-positive, HER2-negative advanced or metastatic breast cancer.
In combination with fulvestrant: For adults with HR-positive, HER2-negative advanced or metastatic breast cancer whose disease has progressed following endocrine therapy.
As adjuvant therapy with tamoxifen or an aromatase inhibitor: For early-stage, node-positive HR-positive, HER2-negative breast cancer at a high risk of recurrence and a Ki-67 score ≥20%.
These treatment options provide oncologists with the flexibility to tailor therapy based on the disease stage and previous treatments.
Dosage & Administration
Abeclib 150 mg is typically taken twice daily (every 12 hours) with or without food. The tablets should be swallowed whole with water and not crushed or chewed. Dosage may vary depending on the combination regimen and patient tolerance.
In monotherapy or with fulvestrant/aromatase inhibitors: 150 mg twice daily
Dose adjustments may be necessary based on side effects or lab test results
Always follow the dosage instructions provided by the oncologist, and do not self-adjust the dose.
Common Side Effects
While Abeclib is generally well-tolerated, some patients may experience side effects. Common side effects include:
Diarrhea (very common)
Fatigue
Nausea and vomiting
Neutropenia (low white blood cell count)
Anemia
Elevated liver enzymes
Appetite loss
Patients should be closely monitored for blood cell counts and liver function during treatment. Supportive medications may be prescribed to manage side effects such as diarrhea or neutropenia.
Precautions & Warnings
Pregnancy & Breastfeeding: Not recommended. Abemaciclib may cause harm to the unborn baby. Women of reproductive age should use effective contraception during treatment and for at least three weeks after the last dose.
Liver Impairment: Use with caution; dose adjustment may be necessary.
Drug Interactions: Avoid strong CYP3A inhibitors or inducers as they may affect how the drug is metabolized.
Monitoring: Frequent monitoring of CBC, ALT, AST, and bilirubin levels is required.
Manufacturer – Eskayef Pharmaceuticals Ltd.
Eskayef Pharmaceuticals Ltd., based in Bangladesh, is one of the most reputed names in the pharmaceutical industry. Founded in 1990 following the acquisition of SK&F Bangladesh by Transcom Group, Eskayef has built a global reputation for innovation, quality, and regulatory compliance.
Eskayef’s production facilities are certified by UK MHRA, EU GMP, TGA Australia, and WHO GMP, making it a trusted partner in both local and international markets. Abeclib is produced in their state-of-the-art oncology facility with stringent quality control to meet international standards.
Website: www.skfbd.com
Supplier – Saif Pharma
Saif Pharma is a globally trusted supplier and distributor of oncology medicines, including Abeclib 150 mg. Established in 2014, Saif Pharma has built a reliable network across 60+ countries.
Saif Pharma is known for:
Competitive pricing on high-quality oncology medicines
Fast and safe international delivery
Expert consultation and support for hospitals, pharmacies, and patients
Comprehensive sourcing for rare cancer treatments
Their mission is to ensure accessibility to effective cancer care at an affordable cost.
Website: www.saifpharma.com
Why Choose Abeclib 150 mg?
Targeted Therapy: Acts specifically on CDK4/6 to stop cancer cell proliferation
Flexible Treatment: Can be used alone or with other hormonal agents
Clinical Effectiveness: Proven to extend progression-free survival
High-Quality Manufacturing: Produced under strict GMP guidelines by Eskayef
Global Availability: Distributed efficiently by Saif Pharma worldwide
Frequently Asked Questions (FAQs)
Q: How long should I take Abeclib 150 mg?
A: Duration of treatment depends on your condition and how well you respond. Some patients remain on therapy for months or years under medical supervision.
Q: Can Abeclib be taken with food?
A: Yes, Abeclib can be taken with or without food.
Q: Is regular blood testing required?
A: Yes, frequent CBC and liver function tests are essential to monitor your safety during treatment.
Q: Can men use Abeclib?
A: Yes, Abeclib is also approved for use in men with HR+, HER2- metastatic breast cancer.
Conclusion
Abeclib 150 mg (Abemaciclib) is a breakthrough treatment option for patients with HR-positive, HER2-negative breast cancer, offering hope where previous therapies have failed. Whether used as monotherapy or in combination with hormonal agents, Abeclib delivers targeted and clinically proven results.
Manufactured by Eskayef Pharmaceuticals Ltd. and distributed worldwide by Saif Pharma, this product is a reliable choice for oncologists and patients alike. With high standards of quality and a mission to make treatment more accessible, Abeclib stands out as a symbol of progress in cancer care.
